Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subconjunctival mitomycin C as adjunctive therapy before pterygium excision.

Eric D Donnenfeld1, Henry D Perry, Susan Fromer

  • 1Nassau University Medical Center, East Meadow, New York, USA. eddoph@aol.com

Ophthalmology
|May 17, 2003
PubMed
Summary

Subconjunctival mitomycin C injections before pterygium surgery effectively reduced recurrence rates to 6% with no complications. This method precisely targets activated fibroblasts, minimizing toxicity for pterygium treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Femtosecond Laser-Assisted Lamellar Keratectomy in the Treatment of Granular Corneal Dystrophy.

Cornea·2026
Same author

Inverse Bell Phenomenon and Superior Keratoconus.

Cornea·2026
Same author

Postoperative Inflammation and Pain Management with Intracanalicular Dexamethasone Insert: Real-World Applications.

Ophthalmology and therapy·2026
Same author

Impact of lotilaner ophthalmic solution 0.25% on disease severity in patients with <i>Demodex</i> blepharitis and meibomian gland disease.

Frontiers in medicine·2026
Same author

Advancing Understanding of Ligneous Conjunctivitis: Bridging Pathogenesis, Diagnosis, and Therapy.

Cornea·2025
Same author

Real-World Experience with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: A Provider Survey in the USA and Canada.

Ophthalmology and therapy·2025

Area of Science:

  • Ophthalmology
  • Surgical Oncology

Background:

  • Pterygium is a common ocular surface condition.
  • Surgical excision is the primary treatment for pterygium.
  • Recurrence after pterygium surgery can occur.

Purpose of the Study:

  • To assess the safety and efficacy of subconjunctival mitomycin C (MMC) as a pre-operative adjunctive therapy for pterygium.
  • To evaluate the recurrence rates and wound healing following pterygium excision after MMC treatment.

Main Methods:

  • A prospective, noncomparative case series involving 36 patients.
  • Subconjunctival injection of 0.1 ml of 0.15 mg/ml MMC into the pterygium head one month prior to surgery.
  • Standard bare sclera surgical excision was performed.

Related Experiment Videos

Main Results:

  • Pterygia resolved in 34 out of 36 eyes (94%).
  • A low recurrence rate of 6% was observed over a mean follow-up of 24.4 months.
  • No wound-healing complications were reported in any patient.

Conclusions:

  • Subconjunctival mitomycin C is a safe and effective adjunctive treatment prior to pterygium excision.
  • The subconjunctival route allows for precise drug delivery to fibroblasts, reducing epithelial toxicity.
  • This approach shows promise in reducing pterygium recurrence rates.